Adolescent Medicine
Latest News
Nemolizumab Benefits for Atopic Dermatitis Maintained in Long-Term Follow-Up Study
Nemolizumab was associated with “ongoing clinically meaningful improvements in itch, skin lesions, and sleep disturbance,” reported Dr. Diamant...
Feature
IBS: Understanding a Common Yet Misunderstood Condition
Today, several dietary, pharmacologic, and psychological/behavioral approaches are available to treat patients with IBS.
From the Journals
Cannabis Use Linked to Brain Thinning in Adolescents
Tetrahydrocannabinol (THC) causes shrinkage of dendritic arborization — the neurons’ network of antennae that play a critical role in...
Latest News
Atopic Dermatitis: Upadacitinib Effectiveness Maintained Through 76 weeks Among Adolescents
Among those who continued treatment on upadacitinib, 15 mg and 30 mg, EASI-75 response rates were maintained or improved through week 76 in three...
From the Journals
A New, Easily Identifiable Sign of Concussion?
Spontaneous Headshake After a Kinematic Event (SHAAKE) refers to the rapid, back-and-forth head movement athletes exhibit following a blow to the...
Latest News
Over 3 Years, Atopic Dermatitis Well-Controlled with Lebrikizumab
“Over the whole follow-up, 90% had no need for topical corticosteroids or any other rescue therapy,” reported Diamant Thaçi, MD, PhD.
Latest News
State of Confusion: Should All Children Get Lipid Labs for High Cholesterol?
Screening rates are low and usually linked to BMI, even though roughly one in four children with abnormal lipids had a normal weight.
Conference Coverage
Wide Availability of Naloxone and Education on Its Use Can Save Pediatric Lives
Study data highlight and underscore naloxone’s safety of use in the prehospital setting.
Latest News
Childhood-Onset Atopic Dermatitis Adds Burden in Adulthood
The Scars of Life project was designed to analyze how the age of AD onset affects the severity of symptoms and quality of life.
Latest News
Guidance Will Aid Pediatric to Adult Diabetes Care Transfer
The care transition period is critical because “adolescents and young adults are the least likely of all age groups to achieve glycemic targets...
Latest News
FDA Approves IL-13 inhibitor for Atopic Dermatitis
Approval was based on results from ADvocate 1, ADvocate 2, and...